| Acute myeloid leukaemia NJ Short, ME Rytting, JE Cortes The Lancet 392 (10147), 593-606, 2018 | 671 | 2018 |
| Advances in the treatment of acute myeloid leukemia: new drugs and new challenges NJ Short, M Konopleva, TM Kadia, G Borthakur, F Ravandi, CD DiNardo, ... Cancer discovery 10 (4), 506-525, 2020 | 261 | 2020 |
| Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis NJ Short, S Zhou, C Fu, DA Berry, RB Walter, SD Freeman, CS Hourigan, ... JAMA oncology 6 (12), 1890-1899, 2020 | 257 | 2020 |
| New Oral Anticoagulants and the Cancer Patient. NJ Short, JM Connors The Oncologist, 2013 | 257 | 2013 |
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ... The Lancet Haematology 7 (10), e724-e736, 2020 | 246 | 2020 |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single … E Jabbour, NJ Short, F Ravandi, X Huang, N Daver, CD DiNardo, ... The Lancet Haematology 5 (12), e618-e627, 2018 | 223 | 2018 |
| Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia NJ Short, E Jabbour, K Sasaki, K Patel, SM O’Brien, JE Cortes, R Garris, ... Blood, The Journal of the American Society of Hematology 128 (4), 504-507, 2016 | 221 | 2016 |
| Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase … H Kantarjian, F Ravandi, NJ Short, X Huang, N Jain, K Sasaki, N Daver, ... The Lancet Oncology 19 (2), 240-248, 2018 | 216 | 2018 |
| Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ... Journal of Clinical Oncology 39 (25), 2768-2778, 2021 | 209 | 2021 |
| Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN E Jabbour, NJ Short, G Montalban-Bravo, X Huang, C Bueso-Ramos, ... Blood, The Journal of the American Society of Hematology 130 (13), 1514-1522, 2017 | 177 | 2017 |
| Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: a propensity … K Sasaki, EJ Jabbour, F Ravandi, NJ Short, DA Thomas, ... Cancer 122 (23), 3650-3656, 2016 | 177 | 2016 |
| Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia R Assi, H Kantarjian, NJ Short, N Daver, K Takahashi, G Garcia-Manero, ... Clinical Lymphoma Myeloma and Leukemia 17 (12), 897-901, 2017 | 150 | 2017 |
| Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions B Samra, E Jabbour, F Ravandi, H Kantarjian, NJ Short Journal of hematology & oncology 13, 1-17, 2020 | 144 | 2020 |
| Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic … E Jabbour, F Ravandi, P Kebriaei, X Huang, NJ Short, D Thomas, ... JAMA oncology 4 (2), 230-234, 2018 | 140 | 2018 |
| Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens CA Lachowiez, S Loghavi, TM Kadia, N Daver, G Borthakur, ... Blood advances 4 (7), 1311-1320, 2020 | 130 | 2020 |
| Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia NJ Short, H Kantarjian, F Ravandi, N Daver Therapeutic Advances in Hematology 10, 2040620719827310, 2019 | 118 | 2019 |
| Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia NJ Short, G Montalban-Bravo, H Hwang, J Ning, MJ Franquiz, ... Blood advances 4 (22), 5681-5689, 2020 | 114 | 2020 |
| Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts NJ Short, E Jabbour, M Albitar, M de Lima, L Gore, J Jorgensen, ... American journal of hematology 94 (2), 257-265, 2019 | 113 | 2019 |
| De novo acute myeloid leukemia: a population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 K Sasaki, F Ravandi, TM Kadia, CD DiNardo, NJ Short, G Borthakur, ... Cancer 127 (12), 2049-2061, 2021 | 107 | 2021 |
| Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic … TM Kadia, PK Reville, G Borthakur, M Yilmaz, S Kornblau, Y Alvarado, ... The Lancet Haematology 8 (8), e552-e561, 2021 | 102 | 2021 |
